# Symbiotec Pharmalab IPO to raise ₹1,757 crore from August 24 2026-08-19T17:18:14+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 2 independent outlets Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, will launch its initial public offering on August 24 to raise ₹1,757 crore. The price band is fixed at ₹938-988 per share, valuing the company at about ₹6,350 crore at the higher end. The issue comprises a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore from promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund-III. The Hindu Businessline reports the company claims a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs. LiveMint reports a grey market premium of ₹320 on Friday, suggesting a potential listing gain of 32.4%. The IPO proceeds from the fresh issue will be used for debt repayment and general corporate purposes. The equity shares are proposed to list on the BSE and NSE on September 1. ## Indian Opinion Analysis Both sources provide neutral, wire-style coverage of Symbiotec Pharmalab's IPO, with no discernible editorial slant. The Hindu Businessline leads with the company's global market leadership in corticosteroids, while LiveMint offers a detailed procedural checklist for investors, including grey market premium. The uniform straight reporting means a careful reader should focus on the ₹1,757 crore raise, the 32% GMP indicating strong demand, and the August 24 opening. Watch for the September 1 listing, which will test whether the premium materialises. ## Coverage Coverage: 2 sources, 2 neutral - thehindubusinessline.com (neutral report) Leads with the company's global leadership in corticosteroids and financials before procedural details. - livemint.com (neutral report) Frames story as investor guide with GMP and lot size, emphasising market opportunity. This story was synthesised by AI from the 2 sources linked above. Updated: this story now draws on 2 sources. Last updated 2026-08-21T16:31:10+00:00. Tags: BSE, IPO, Motilal Oswal, NSE, Rosewood Investments, Symbiotec Pharmalab Canonical: https://indianopinion.org/symbiotec-pharmalab-to-raise-rs-1757-crore-via-ipo/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/symbiotec-pharmalab-to-raise-rs-1757-crore-via-ipo/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/